Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...

An indigenously developed CAR T-cell gene therapy has achieved a 73% response rate for certain blood cancers in India. The ...

In a groundbreaking moment for cancer, Chinese researchers turned the immune response provoked by organ transplants to fight ...

Researchers have discovered that cancer cells suppress 'poison exons' -- genetic elements that act as an off switch for protein production -- in a key gene called TRA2 , promoting tumor growth. By ...

In this interview, News Medical speaks with Olivier Negre, Chief Scientific Officer at Smart Immune, about how immunotherapy is being revolutionized.

Biotherapeutics announced promising preclinical results for its systemic RTNova platform. The platform has successfully delivered ...

The approach isn't new. App developers sometimes seek financial support from avid users and medical research institutions ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

An Indian-developed gene therapy for certain blood cancers has shown a 73 per cent response rate among patients in India. The results of the clinical trials were published in The Lancet ...